Sep 2026· Proteomics· pp.
e70178
· 0 citations· 23 references
Medicine
TL;DR
There was no evidence of astrogliosis after microglia ablation as determined by proteome analysis and brain histology, crucial for interpreting changes to the CSF proteome in relation to neuroinflammatory changes in neurological diseases.
Abstract
Disease-related activation of glial cells leads to changes in the cerebrospinal fluid (CSF) proteome. However, assigning such protein changes to their cellular origins is often difficult. Here, we used microglia (and macrophage) depletion in mice to identify CSF proteins of microglial origin. Young mice were treated with an inhibitor of the colony-stimulating factor 1 receptor, resulting in an almost complete ablation of microglial cells (and brain macrophages). Depleting microglia revealed profound changes in the CSF proteome. Nineteen proteins showed an overall reduction of at least 90%, suggesting a direct microglial or macrophage origin. Strikingly, we also observed an increase in many neuronal and synaptic proteins, likely reflecting compensatory neural changes including the accumulation of certain neuronal proteins that normally act as ligands for receptors on microglia cells, such as fractalkine or interleukin-34. In contrast to the robust changes in microglial and neuronal proteins, there was no evidence of astrogliosis after microglia ablation as determined by proteome analysis and brain histology. These observations are crucial for interpreting changes to the CSF proteome in relation to neuroinflammatory changes in neurological diseases.
It was found that AD was characterized by altered microglial composition and rewiring of intercellular communication, including disease-specific signaling pathways and distinct interaction hubs.
Loren dos Santos, R. Vialle, Natacha Comandante-Lou et al.· bioRxiv· 0 citations
Advanced fluid biomarkers, such as seed amplification assays (SAA), alongside multidimensional neuroimaging techniques (PET, SPECT, MRI), are proving crucial for detecting these early microglial and pathological changes to guide personalized, disease-modifying therapies of PD.
Manuel Debasa-Mouce, Alberto Ouro, J. De Leon et al.· Advances in Immunology· 0 citations
Neuronal pathology plays a prominent role in the cognitive and neuropathic symptoms of multiple sclerosis; however, little is known about these pathological signals to neurons in the brain and their consequences on cognition. Here, using a transgenic reporter of IFN signaling with spatial RNA-sequencing, we determined...
Shane M. O'Neil, H. Min, Li Xu et al.· bioRxiv· 0 citations
This work situates MiET formation within the broader microglial functional repertoire and focuses on how ET-dominant responses may compromise homeostatic or neuroprotective roles, expanding the conceptual framework for microglial pathogenicity and inviting future mechanistic and translational research.
Lipika Sha, Sushmita Jha· Advances in Immunology· 0 citations
Neuroimmune responses critically shape the progression and outcome of ischemic stroke, yet the cell type-specific roles of myeloid populations remain incompletely defined. Cathepsin B (CatB), a lysosomal cysteine protease, has been implicated in neuroinflammation, but its contribution from distinct myeloid subsets is u...
Chronic microglial activation and the resulting neuroinflammatory cascade drive Alzheimer's disease (AD) progression. Systemic lipopolysaccharide (LPS) triggers robust microglial responses and is linked to neurodegenerative disorders, yet the full spectrum of neuroinflammatory and neuronal changes associated with chron...
Li Niu, Chen-Jing Yang, Yu-Bo Li et al.· Neuroscience Letters· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.